KR102133610B1 - 인지증 치료제 또는 예방제 - Google Patents

인지증 치료제 또는 예방제 Download PDF

Info

Publication number
KR102133610B1
KR102133610B1 KR1020147035417A KR20147035417A KR102133610B1 KR 102133610 B1 KR102133610 B1 KR 102133610B1 KR 1020147035417 A KR1020147035417 A KR 1020147035417A KR 20147035417 A KR20147035417 A KR 20147035417A KR 102133610 B1 KR102133610 B1 KR 102133610B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
ser
gly
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035417A
Other languages
English (en)
Korean (ko)
Other versions
KR20150027098A (ko
Inventor
히로시 모리
다카미 도미야마
요이치 마츠모토
히로시 에구치
유이치 구노리
Original Assignee
고리쓰다이가쿠호진 오사카 시리쓰다이가쿠
데이진 화-마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠, 데이진 화-마 가부시키가이샤 filed Critical 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠
Publication of KR20150027098A publication Critical patent/KR20150027098A/ko
Application granted granted Critical
Publication of KR102133610B1 publication Critical patent/KR102133610B1/ko
Assigned to 코우리츠 다이가꾸 호우진 오사카 reassignment 코우리츠 다이가꾸 호우진 오사카 권리지분의 전부이전등록 Assignors: 고리쓰다이가쿠호진 오사카 시리쓰다이가쿠
Assigned to 데이진 가부시키가이샤 reassignment 데이진 가부시키가이샤 권리지분의 전부이전등록 Assignors: 데이진 화-마 가부시키가이샤
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020147035417A 2012-05-31 2013-05-30 인지증 치료제 또는 예방제 Active KR102133610B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012124336 2012-05-31
JPJP-P-2012-124336 2012-05-31
PCT/JP2013/065090 WO2013180238A1 (ja) 2012-05-31 2013-05-30 認知症治療剤又は予防剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207007010A Division KR102208283B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제

Publications (2)

Publication Number Publication Date
KR20150027098A KR20150027098A (ko) 2015-03-11
KR102133610B1 true KR102133610B1 (ko) 2020-07-14

Family

ID=49673425

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147035417A Active KR102133610B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제
KR1020207007010A Active KR102208283B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207007010A Active KR102208283B1 (ko) 2012-05-31 2013-05-30 인지증 치료제 또는 예방제

Country Status (30)

Country Link
US (3) US20150183854A1 (https=)
EP (2) EP2857039B1 (https=)
JP (3) JP5971659B2 (https=)
KR (2) KR102133610B1 (https=)
CN (1) CN104602708B (https=)
AR (1) AR091218A1 (https=)
AU (2) AU2013268364B2 (https=)
BR (1) BR112014029566A2 (https=)
CA (1) CA2875205C (https=)
CY (1) CY1122530T1 (https=)
DK (1) DK2857039T3 (https=)
ES (2) ES2973070T3 (https=)
HR (1) HRP20192267T1 (https=)
HU (1) HUE046919T2 (https=)
IL (1) IL235899B (https=)
LT (1) LT2857039T (https=)
ME (1) ME03587B (https=)
MX (1) MX361128B (https=)
MY (1) MY172458A (https=)
NZ (1) NZ630536A (https=)
PH (1) PH12014502669B1 (https=)
PL (1) PL2857039T3 (https=)
PT (1) PT2857039T (https=)
RS (1) RS59802B1 (https=)
RU (1) RU2657438C2 (https=)
SG (2) SG10201805410XA (https=)
SI (1) SI2857039T1 (https=)
TW (2) TWI700296B (https=)
WO (1) WO2013180238A1 (https=)
ZA (1) ZA201409186B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
JP6457263B2 (ja) * 2011-05-20 2019-01-23 オリゴメリックス インコーポレイテッド タウプロテアーゼ組成物および使用方法
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
SG10201708959WA (en) 2012-07-03 2017-11-29 Univ Washington Antibodies to tau
TWI734975B (zh) * 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP6785372B2 (ja) * 2016-09-30 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ
SG11201907422RA (en) 2017-02-17 2019-09-27 Denali Therapeutics Inc Anti-tau antibodies and methods of use thereof
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
AR112600A1 (es) 2017-05-30 2019-11-20 Teijin Pharma Ltd Anticuerpo anti-receptor de igf-i
EP3691639B1 (en) 2017-10-02 2023-11-15 Merck Sharp & Dohme LLC Chromane monobactam compounds for the treatment of bacterial infections
AU2018352308B2 (en) 2017-10-16 2025-06-05 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
EP4471152A3 (en) 2018-04-06 2025-03-26 Teijin Pharma Limited Spns2 neutralizing antibody
EP3819378A4 (en) 2018-07-04 2022-09-14 Aichi Medical University OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES
CN110028583B (zh) * 2019-05-07 2020-09-11 温州医科大学 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
JP7429404B2 (ja) * 2019-08-06 2024-02-08 慶應義塾 タウ関連疾患モデルの製造方法
US20220365102A1 (en) 2019-09-30 2022-11-17 Nipro Corporation Tau protein detection method using blood sample as test specimen
IL296611A (en) * 2020-03-19 2022-11-01 Vascular Biosciences Car peptide for improved coronavirus survival
CA3183835A1 (en) 2020-06-25 2021-12-30 Jeanne E. Baker High affinity antibodies targeting tau phosphorylated at serine 413
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
KR20250069606A (ko) 2022-09-15 2025-05-19 보이저 테라퓨틱스, 인크. 타우 결합 화합물
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS587390B2 (ja) 1975-03-11 1983-02-09 ツキシマキカイ カブシキガイシヤ ア−クヨウセツホウホウ
JP3587390B2 (ja) 1994-03-17 2004-11-10 タカラバイオ株式会社 リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US20070280935A1 (en) * 2006-04-07 2007-12-06 Bernd Bohrmann Antibody that recognizes phosphorylated peptides
EP2028932A4 (en) * 2006-06-16 2011-10-12 Vitruvean Llc TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY
UA107571C2 (xx) * 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20120244174A1 (en) * 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
TR201102696U (tr) * 2011-05-27 2011-06-21 Turhal Sal�H Bağlantısız hareketli ürün reklam standı.
PL2857039T3 (pl) * 2012-05-31 2020-05-18 Osaka City University Środek terapeutyczny lub środek profilaktyczny na otępienie
JP2018139530A (ja) * 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034145A1 (fr) 1996-03-13 1997-09-18 Mitsubishi Chemical Corporation Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant
WO2010144711A2 (en) * 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
JP2012530055A (ja) 2009-06-10 2012-11-29 ニューヨーク・ユニバーシティ 病理学的タウタンパク質の免疫学的標的化方法

Also Published As

Publication number Publication date
MY172458A (en) 2019-11-26
CY1122530T1 (el) 2021-01-27
PH12014502669B1 (en) 2020-02-19
HUE046919T2 (hu) 2020-04-28
PH12014502669A1 (en) 2015-02-02
JPWO2013180238A1 (ja) 2016-01-21
TW202041532A (zh) 2020-11-16
ZA201409186B (en) 2015-12-23
AU2018200413B2 (en) 2019-10-17
US20220340646A1 (en) 2022-10-27
AU2013268364B2 (en) 2018-02-08
AU2013268364A1 (en) 2014-12-18
MX2014014187A (es) 2015-06-04
RS59802B1 (sr) 2020-02-28
JP5971659B2 (ja) 2016-08-17
US20200148753A1 (en) 2020-05-14
EP2857039A1 (en) 2015-04-08
JP2018111716A (ja) 2018-07-19
RU2014153099A (ru) 2016-07-20
SG10201805410XA (en) 2018-08-30
HK1210031A1 (en) 2016-04-15
CN104602708A (zh) 2015-05-06
IL235899A0 (en) 2015-01-29
ME03587B (me) 2020-07-20
NZ630536A (en) 2017-03-31
PT2857039T (pt) 2020-01-07
CA2875205C (en) 2021-07-20
HRP20192267T1 (hr) 2020-03-20
CA2875205A1 (en) 2013-12-05
CN104602708B (zh) 2021-11-30
EP2857039B1 (en) 2019-11-20
JP6620829B2 (ja) 2019-12-18
ES2973070T3 (es) 2024-06-18
JP6406678B2 (ja) 2018-10-17
EP3662931A1 (en) 2020-06-10
US20150183854A1 (en) 2015-07-02
EP3662931B1 (en) 2023-12-06
TWI700296B (zh) 2020-08-01
EP2857039A4 (en) 2015-08-26
AR091218A1 (es) 2015-01-21
DK2857039T3 (da) 2019-12-16
MX361128B (es) 2018-11-28
IL235899B (en) 2019-03-31
AU2018200413A1 (en) 2018-02-08
PL2857039T3 (pl) 2020-05-18
SI2857039T1 (sl) 2020-03-31
KR20150027098A (ko) 2015-03-11
BR112014029566A2 (pt) 2017-07-25
LT2857039T (lt) 2020-03-10
TWI777183B (zh) 2022-09-11
KR102208283B1 (ko) 2021-01-26
JP2016147902A (ja) 2016-08-18
KR20200029619A (ko) 2020-03-18
SG11201407878VA (en) 2015-01-29
WO2013180238A1 (ja) 2013-12-05
RU2657438C2 (ru) 2018-06-13
TW201410705A (zh) 2014-03-16
ES2763361T3 (es) 2020-05-28

Similar Documents

Publication Publication Date Title
KR102133610B1 (ko) 인지증 치료제 또는 예방제
RU2760334C2 (ru) Моноклональные антитела к альфа-синуклеину для предотвращения агрегации тау-белка
JP7012004B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
RU2727911C2 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JP2018139530A (ja) 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
TW202400643A (zh) 神經退化性疾病之治療劑
HK40031828A (en) Therapeutic agent or prophylactic agent for dementia
HK40031828B (en) Therapeutic agent or prophylactic agent for dementia
KR20260047599A (ko) 신경 변성 질환의 치료제
HK1210031B (zh) 痴呆症治疗药或预防药

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180523

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190705

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20200113

Patent event code: PE09021S02D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200310

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200616

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200707

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200707

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230626

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240624

Start annual number: 5

End annual number: 5